Redeye retains its positive view on Vertiseit following a Q2 showing solid organic ARR growth. While comparable ARR and adjusted EBITDA beat our forecasts, management’s forward-looking comments were more cautious than we expected.
ANNONS
Redeye retains its positive view on Vertiseit following a Q2 showing solid organic ARR growth. While comparable ARR and adjusted EBITDA beat our forecasts, management’s forward-looking comments were more cautious than we expected.